Patents by Inventor Véronique TAUPIN

Véronique TAUPIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VARIANT RNAi AGAINST ALPHA-SYNUCLEIN
    Publication number: 20210309999
    Abstract: Provided herein are RNAi molecules for treating neurodegenerative synucleinopathies. In some embodiments, the RNAi molecules target expression of alpha-synuclein (SNCA). Further provided herein are expression constructs, vectors (e.g rAAV), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat neurodegenerative synucleinopathies including Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies.
    Type: Application
    Filed: August 2, 2019
    Publication date: October 7, 2021
    Applicant: Genzyme Corporation
    Inventors: Bradford ELMER, Brenda RICHARDS, Martine LATTA-MAHIEU, Maria Carmen OBINU, Véronique TAUPIN, Véronique BLANCHARD
  • NEURONAL CELL PROTECTIVE EFFECT OF ANTIBODIES SPECIFIC FOR THE PROTOFIBRILLAR FORM OF THE BETA-AMYLOID PEPTIDE
    Publication number: 20190389942
    Abstract: The present invention relates to an antibody specific for the protofibrillar form of the A? peptide for use in the prevention and/or the treatment of a neurodegenerative disease involving A? peptide aggregation, in particular for the prevention of Alzheimer's disease and/or the treatment of an early stage of symptomatic Alzheimer's disease. The antibody may thus be used before the appearance of memory loss and impaired cognitive functions or at the earliest stages of the disease. Said antibody has indeed a neuronal cell protective effect against A? peptide-induced neurotoxicity.
    Type: Application
    Filed: January 30, 2018
    Publication date: December 26, 2019
    Inventors: Véronique TAUPIN, Jean-François DEDIEU, Caroline COHEN, Philippe BERTRAND
  • PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
    Publication number: 20160354445
    Abstract: The present invention refers to a pharmaceutical composition for use in the treatment of a neurodegenerative disease.
    Type: Application
    Filed: May 4, 2016
    Publication date: December 8, 2016
    Inventors: Sibylle HESS, Christian HOELSCHER, Andrees BOEHME, Agnes MENUT, Laurent PRADIER, Veronique TAUPIN
  • Pharmaceutical composition for use in the treatment of a neurodegenerative disease
    Patent number: 9364519
    Abstract: The present application relates to a pharmaceutical composition for use in the prevention or/and treatment of a neurodegenerative disease, the composition comprising desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, adjuvant, or/and auxiliary substance. In addition, the present application relates to the use of the pharmaceutical composition for the treatment and prevention of a neurodegenerative disease.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: June 14, 2016
    Assignees: SANOFI-AVENTIS DEUTSCHLAND GMBH, UNIVERSITY OF ULSTER
    Inventors: Sibylle Hess, Christian Hoelscher, Andrees Boehme, Agnes Menut, Laurent Pradier, Veronique Taupin
  • PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
    Publication number: 20130116179
    Abstract: The present invention refers to a pharmaceutical composition for use in the treatment of a neurodegenerative disease.
    Type: Application
    Filed: September 4, 2012
    Publication date: May 9, 2013
    Applicants: UNIVERSITY OF ULSTER, SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Sibylle HESS, Christian HOELSCHER, Andrees BOEHME, Agnes MENUT, Laurent PRADIER, Veronique TAUPIN
  • Use of benzonaphthalene derivatives to make medicaments for treating diseases of the central nervous system
    Patent number: 6043280
    Abstract: This invention relates to the use of benzonaphthalene compounds for the treatment of peripheral neuropathies, central neurodegenerative diseases and autoimmune diseases of the nervous system.
    Type: Grant
    Filed: January 8, 1999
    Date of Patent: March 28, 2000
    Assignee: Galderma Research & Development, S.N.C.
    Inventors: Xavier Vige, Jesus Benavides, Braham Shroot, Veronique Taupin